TrialInternational journal of clinical oncology2019

Three-year follow-up of a phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer and bone metastases.

Hirotsugu Uemura et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.